Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CAL02 · 1 trial · 1 indication
To evaluate the effect of CAL02 administration on clinical recovery compared to placebo. The time (days) to clinical recovery will be measured, as defined by the day all disease severity criteria which led to SCABP diagnosis per protocol at randomization and any new severity criteria which occurred after randomization are resolved, and no repeat or additional severity criteria are met within 24 hours after clinical recovery.
To evaluate the safety and tolerability of CAL02 versus placebo. The number of participants with treatment-emergent adverse events including IV infusion-related reactions, and the number of participants with study drug dosing interruptions and discontinuations will be measured.
| Arm | Type | Description |
|---|---|---|
| CAL02 with Standard of Care | EXPERIMENTAL | CAL02 (a mixture of 2 liposomal components, both empty, unilamellar, liposomes) will be administered as 2, IV infusions, 24 - 26 hours apart in addition to Standard of Care therapy for SCABP, according to scientific guidelines. CAL02 infusions will be administered over a 1 -2 hour period. |
| Placebo | PLACEBO_COMPARATOR | Placebo will be administered as 2, IV infusions, 24 - 26 hours apart in addition to Standard of Care therapy for SCABP, according to scientific guidelines. Placebo will be prepared and administered following the same infusion protocol as CAL02. Placebo infusions will be administered over a 1 to 2 hour period. |
| Name | Type | Description |
|---|---|---|
| CAL02 | DRUG | CAL02 consists of a mixture of 2 liposomes and is a non-biological bacterial virulence neutralizer. |
| Placebo | DRUG | Physiological 0.9% sodium chloride solution for iv administration |
Inclusion Criteria: * male or females older than 18 years old * Body Weight 40 - 140 kg; * clinical diagnosis of CABP diagnosed less than or equal to 48 hrs after hospital admission; * presence of at least one of the protocol defined SCABP severity criteria: * at least two clinical symptoms * at le...